Dr Reddy's submits response to USFDA over warning letter
New Delhi: Dr Reddy's Laboratories has submitted a response to the US health regulator on a warning letter it had received last month."We would like to inform that the company has submitted a response to the US Food and Drug Administration (USFDA) on December 7", Dr Reddy's Laboratories said in a filing to the BSE.Last month, the country's second-largest drug maker had received a warning...
Login or Register to read the full article
New Delhi: Dr Reddy's Laboratories has submitted a response to the US health regulator on a warning letter it had received last month.
"We would like to inform that the company has submitted a response to the US Food and Drug Administration (USFDA) on December 7", Dr Reddy's Laboratories said in a filing to the BSE.
Last month, the country's second-largest drug maker had received a warning letter from the USFDA relating to two of its API manufacturing plants and a formulation plant in Andhra Pradesh and Telangana.
In response to the letter, DRL CEO G V Prasad had said the company is in the process of shifting some of the products from these plants to other facilities and considering third party assessment for its plants.
The US agency had asked the drug maker to provide a comprehensive evaluation of the extent of inaccuracies in recorded and reported data and include a detailed action plan to fully investigate the scale and root causes of "deficient documentation and data management practices".
Read also
Dr Reddy’s gets FDA warning letter for three drug plants
"We would like to inform that the company has submitted a response to the US Food and Drug Administration (USFDA) on December 7", Dr Reddy's Laboratories said in a filing to the BSE.
Last month, the country's second-largest drug maker had received a warning letter from the USFDA relating to two of its API manufacturing plants and a formulation plant in Andhra Pradesh and Telangana.
In response to the letter, DRL CEO G V Prasad had said the company is in the process of shifting some of the products from these plants to other facilities and considering third party assessment for its plants.
The US agency had asked the drug maker to provide a comprehensive evaluation of the extent of inaccuracies in recorded and reported data and include a detailed action plan to fully investigate the scale and root causes of "deficient documentation and data management practices".
Read also
Dr Reddy’s gets FDA warning letter for three drug plants
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd